Moderate

Drug-induced lupus erythematosus (DILE)

Drug-induced lupus · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Lupus-like syndrome triggered by a culprit drug, resolving after withdrawal. Features arthralgia/arthritis, myalgia, fever, serositis (pleuritis/pericarditis) and constitutional symptoms; renal and CNS involvement are rare (unlike idiopathic SLE). Classic triggers: hydralazine, procainamide, isoniazid, minocycline, anti-TNF agents, quinidine, methyldopa, chlorpromazine, terbinafine, some anticonvulsants and PD-1/PD-L1 checkpoint inhibitors. Serology: ANA positive with ANTI-HISTONE antibodies (hallmark, though anti-TNF-induced lupus may have anti-dsDNA). Normal complement is typical. Recognition hinges on the drug history.

Red flags

  • Significant proteinuria/active sediment or neuropsychiatric features — suggests idiopathic SLE, not DILE; reassess
  • Large pericardial effusion/tamponade physiology from serositis
  • Symptoms persisting weeks after drug withdrawal — reconsider diagnosis
  • Checkpoint-inhibitor-related lupus — part of immune-related adverse event spectrum, oncology input
  • Anti-TNF-induced lupus — may have anti-dsDNA and need drug-class change

Assessment

Differential diagnosis

  • Idiopathic SLE (renal/CNS/haematologic involvement, anti-dsDNA/Sm, low complement)
  • Viral/reactive arthritis, other drug reactions
  • Rheumatoid arthritis, other CTD
  • Infective serositis, malignancy
  • Subacute cutaneous lupus (also drug-induced — anti-Ro, photosensitive rash)

Investigations

  • Detailed drug/exposure history (timing — usually months of exposure) — the key diagnostic step
  • ANA (positive) + ANTI-HISTONE antibodies (characteristic); anti-dsDNA usually negative (except anti-TNF-induced)
  • Complement C3/C4 (usually NORMAL — helps distinguish from SLE)
  • FBC (cytopenias uncommon), U&E + urinalysis (renal involvement rare — if present reconsider SLE)
  • ESR/CRP; CXR/echo if serositis suspected

Management

  • Identify and STOP the culprit drug — the definitive treatment; symptoms usually resolve over days to weeks
  • Confirm supportive serology (ANA + anti-histone, normal complement, absent major organ disease)
  • Symptomatic treatment while resolving: NSAIDs for arthralgia/serositis
  • Short course of low-moderate glucocorticoids for significant serositis or disabling symptoms
  • Hydroxychloroquine for persistent musculoskeletal/cutaneous symptoms if needed
  • Document and flag the drug allergy; avoid re-exposure and related agents
  • If features atypical, organ involvement, or symptoms persist beyond weeks — reassess for idiopathic SLE

Drugs & doses

STOP the culprit drug (hydralazine, procainamide, isoniazid, minocycline, anti-TNF, etc.) — primary treatment
NSAID e.g. naproxen 500 mg ORALLY twice daily with PPI for arthralgia/serositis
Prednisolone 15-30 mg ORALLY daily short taper for significant serositis/pericarditis [verify local dose]
Hydroxychloroquine 200-400 mg ORALLY daily for persistent cutaneous/articular symptoms [verify local]

Disposition

Outpatient — stop drug, symptomatic treatment, rheumatology follow-up to confirm resolution. Admit only for significant serositis/tamponade. Document drug reaction.

Complications & pitfalls

  • Serositis (pericarditis/pleuritis) — occasionally significant effusions
  • Persistent symptoms if drug not identified
  • Rarely, overlap with evolving idiopathic SLE

Exam pearls

  • The diagnosis is made on the DRUG HISTORY — ANA + anti-histone antibodies with NORMAL complement and no renal/CNS disease is the classic profile.
  • Stopping the drug is curative; symptoms resolve over days to weeks (serology can lag/persist longer).
  • Renal and neurological involvement are rare — if present, think idiopathic SLE instead.
  • Anti-TNF and checkpoint-inhibitor induced lupus are increasingly common and may break the 'anti-histone/normal complement' rule (can have anti-dsDNA).
  • Hydralazine and procainamide are the highest-risk classic culprits (slow acetylators at greater risk).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.